Immuno-PET and immuno-SPECT of rheumatoid arthritis with radiolabeled anti-fibroblast activation protein antibody correlates with severity of arthritis

Journal of Nuclear Medicine

Volumn 56, Issue 5, 2015, Pages 778-783

  Laverman, Peter ^a   Van Der Geest, Tessa ^a   Terry, Samantha Y A ^a,b   Gerrits, Danny ^a   Walgreen, Birgitte ^a   Helsen, Monique M ^a   Nayak, Tapan K ^c   Freimoser Grundschober, Anne ^d   Waldhauer, Inja ^d   Hosse, Ralf J ^d   Moessner, Ekkehard ^d   Umana, Pablo ^d   Klein, Christian ^d   Oyen, Wim J G ^a   Koenders, Marije I ^a   Boerman, Otto C ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^b KING'S COLLEGE LONDON   (United Kingdom)

^c F HOFFMANN LA ROCHE LTD   (Switzerland)

^d Roche Innovation Center Zurich   (Switzerland)

Author keywords

CIA; Fibroblast activation protein (FAP); Monoclonal antibody; Pet imaging; SPECT imaging

Indexed keywords

28H1 INDIUM IN 111; 28H1 ZIRCONIUM ZR 89; DP47GS INDIUM IN 111; PENTETIC ACID; RADIOISOTOPE; RADIOPHARMACEUTICAL AGENT; UNCLASSIFIED DRUG; GELATINASE; INDIUM; MEMBRANE PROTEIN; MONOCLONAL ANTIBODY; SEPRASE; SERINE PROTEINASE; ZIRCONIUM;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BINDING AFFINITY; CONTROLLED STUDY; DISEASE SEVERITY; EXPERIMENTAL ARTHRITIS; IMAGE ANALYSIS; IMAGE DISPLAY; IMMUNOHISTOCHEMISTRY; ISOTOPE LABELING; MALE; MOUSE; NONHUMAN; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; RADIOACTIVITY; SCORING SYSTEM; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; ANIMAL; COMPUTER ASSISTED TOMOGRAPHY; DIAGNOSTIC USE; FIBROBLAST; IMMUNOLOGY; PATHOLOGY; PROCEDURES; RADIOGRAPHY; RHEUMATOID ARTHRITIS; SCINTISCANNING; TISSUE DISTRIBUTION;

ANIMALS; ANTIBODIES, MONOCLONAL; ARTHRITIS, RHEUMATOID; FIBROBLASTS; GELATINASES; INDIUM RADIOISOTOPES; MALE; MEMBRANE PROTEINS; MICE; POSITRON-EMISSION TOMOGRAPHY; SERINE ENDOPEPTIDASES; TISSUE DISTRIBUTION; TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON; TOMOGRAPHY, X-RAY COMPUTED; ZIRCONIUM;

EID: 84929464365     PISSN: 01615505     EISSN: 2159662X     Source Type: Journal    
DOI: 10.2967/jnumed.114.152959     Document Type: Article

References (33)

1. Firestein GS. Invasive fibroblast-like synoviocytes in rheumatoid arthritis: passive responders or transformed aggressors? Arthritis Rheum. 1996;39:1781-1790.
2. Bauer S, Jendro MC, Wadle A, et al. Fibroblast activation protein is expressed by rheumatoid myofibroblast-like synoviocytes. Arthritis Res Ther. 2006;8:R171.
3. Scanlan MJ, Raj BK, Calvo B, et al. Molecular cloning of fibroblast activation protein alpha, a member of the serine protease family selectively expressed in stromal fibroblasts of epithelial cancers. Proc Natl Acad Sci USA. 1994;91:5657-5661.
4. Grinnell F. Fibroblasts, myofibroblasts, and wound contraction. J Cell Biol. 1994;124:401-404.
5. Morimoto C, Schlossman SF. The structure and function of CD26 in the T-cell immune response. Immunol Rev. 1998;161:55-70.
6. Goldstein LA, Ghersi G, Pineiro-Sanchez ML, et al. Molecular cloning of seprase: a serine integral membrane protease from human melanoma. Biochim Biophys Acta. 1997;1361:11-19.
7. Garin-Chesa P, Old LJ, Rettig WJ. Cell surface glycoprotein of reactive stromal fibroblasts as a potential antibody target in human epithelial cancers. Proc Natl Acad Sci USA. 1990;87:7235-7239.
8. Park JE, Lenter MC, Zimmermann RN, Garin-Chesa P, Old LJ, Rettig WJ. Fibroblast activation protein, a dual specificity serine protease expressed in reactive human tumor stromal fibroblasts. J Biol Chem. 1999;274:36505-36512.
9. Welt S, Divgi CR, Scott AM, et al. Antibody targeting in metastatic colon cancer: a phase I study of monoclonal antibody F19 against a cell-surface protein of reactive tumor stromal fibroblasts. J Clin Oncol. 1994;12:1193-1203.
10. Scott AM, Wiseman G, Welt S, et al. A phase I dose-escalation study of sibrotuzumab in patients with advanced or metastatic fibroblast activation protein-positive cancer. Clin Cancer Res. 2003;9:1639-1647.
11. Fischer E, Chaitanya K, Wuest T, et al. Radioimmunotherapy of fibroblast activation protein positive tumors by rapidly internalizing antibodies. Clin Cancer Res. 2012;18:6208-6218.
12. Bacac M, Freimoser-Grundschober A, Hosse R, et al., inventors; Roche Glycart, assignee. Anti-FAP Antibodies and Methods of Use. U.S. patent WO/2012/020006. February 16, 2012.
13. Baehner M, Jenewein S, Kubbies M, Moessner E, Schlothauer T; Roche Glycart, assignee. Antibody Fc variants. U.S. patent WO/2012/130831. October 4, 2013.
14. 111In in HEPES and MES buffer. EJNMMI Res. 2012;2:4.
15. 89Zr-labeled monoclonal antibodies. J Nucl Med. 2003;44:1271-1281.
16. Joosten LA, Helsen MM, van de Loo FA, van den Berg WB. Anticytokine treatment of established type II collagen-induced arthritis in DBA/1 mice: a comparative study using anti-TNF alpha, anti-IL-1 alpha/beta, and IL-1Ra. Arthritis Rheum. 1996;39:797-809.
17. van der Have F, Vastenhouw B, Ramakers RM, et al. U-SPECT-II: an ultra-high-resolution device for molecular small-animal imaging. J Nucl Med. 2009; 50:599-605.
18. Visser EP, Disselhorst JA, Brom M, et al. Spatial resolution and sensitivity of the Inveon small-animal PET scanner. J Nucl Med. 2009;50:139-147.
19. Ibrahim SM, Koczan D, Thiesen HJ. Gene-expression profile of collagen-induced arthritis. J Autoimmun. 2002;18:159-167.
20. Maeda H, Seymour LW, Miyamoto Y. Conjugates of anticancer agents and polymers: advantages of macromolecular therapeutics in vivo. Bioconjug Chem. 1992;3:351-362.
21. Boerman OC, Oyen WJ, Storm G, et al. Technetium-99m labelled liposomes to image experimental arthritis. Ann Rheum Dis. 1997;56:369-373.
22. Heskamp S, van Laarhoven HW, Molkenboer-Kuenen JD, et al. ImmunoSPECT and immunoPET of IGF-1R expression with the radiolabeled antibody R1507 in a triple-negative breast cancer model. J Nucl Med. 2010;51:1565-1572.
23. 177Lu in tumor-bearing nude mice after coupling to the internalizing antibody cetuximab. J Nucl Med. 2005;46:1898-1906.
24. 89Zr-trastuzumab for HER2/neu immunoPET imaging. J Nucl Med. 2009;50:974-981.
25. Kubota K, Ito K, Morooka M, et al. FDG PET for rheumatoid arthritis: basic considerations and whole-body PET/CT. Ann N Y Acad Sci. 2011;1228:29-38.
26. Mountz JM, Alavi A, Mountz JD. Emerging optical and nuclear medicine imaging methods in rheumatoid arthritis. Nat Rev Rheumatol. 2012;8:719-728.
27. van der Laken CJ, Huisman MH, Voskuyl AE. Nuclear imaging of rheumatic diseases. Best Pract Res Clin Rheumatol. 2012;26:787-804.
28. 18F-FDG PET/CT assessments with disease activity and markers of inflammation in patients with early rheumatoid arthritis following the initiation of combination therapy with triple oral antirheumatic drugs. Eur J Nucl Med Mol Imaging. 2013;40:403-410.
29. 18F-FDG positron emission tomography and computed tomography. Arthritis Res Ther. 2010;12:R203.
30. 18F-fluorodeoxyglucose positron emission tomography data. Korean J Radiol. 2012;13:450-457.
31. Kundu-Raychaudhuri S, Mitra A, Datta-Mitra A, Chaudhari AJ, Raychaudhuri SP. In vivo quantification of mouse autoimmune arthritis by PET/CT. Int J Rheum Dis. June 26, 2014 [Epub ahead of print].
32. 18F-FDG uptake by cells involved in pannus formation in rheumatoid arthritis. J Nucl Med. 2009;50:920-926.
33. Tran E, Chinnasamy D, Yu Z, et al. Immune targeting of fibroblast activation protein triggers recognition of multipotent bone marrow stromal cells and cachexia. J Exp Med. 2013;210:1125-1135.